olaparib placebo

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC, AstraZeneca

Conditions

Endometrial NeoplasmsNon-small cell lung cancer

Phase 3

Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

Active, not recruitingNCT04269200

AstraZenecaEndometrial Neoplasms

Start: 2020-05-05End: 2027-04-01Updated: 2026-08-07

A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib vs Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer (NSCLC)

Active, not recruitingCTIS2023-503591-25-00

Merck Sharp & Dohme LLCNon-small cell lung cancer

Start: 2020-06-09Target: 295Updated: 2025-09-22

Related Papers

Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer: Japan subset from the phase III DUO-E trial.

2025-07-01

Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for endometrial cancer: Longitudinal changes in circulating tumor DNA.

Journal of Clinical Oncology2025-05-287 citations

Real-world patient characteristics and survival outcomes in patients with advanced or recurrent endometrial cancer in England: a retrospective, population-based study

BMJ Open2024-11-011 citations

Durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer (EC) in DUO-E: Results by <i>BRCA1</i>/<i>BRCA2</i> mutation (BRCAm) status.

Journal of Clinical Oncology2024-06-012 citations

Safety and tolerability of durvalumab + carboplatin/paclitaxel followed by durvalumab ± olaparib in patients with newly diagnosed advanced or recurrent endometrial cancer (EC) in the DUO-E/GOG-3041/ENGOT-EN10 trial.

Journal of Clinical Oncology2024-06-011 citations

619 Durvalumab plus carboplatin/paclitaxel followed by durvalumab ± olaparib as a first-line treatment for newly diagnosed advanced or recurrent endometrial cancer: results from the phase III DUO-E/GOG-3041/ENGOT-EN10 Trial

2024-03-011 citations

Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer.

2024-02-2984 citations

Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma.

2023-03-1518 citations

DUO-E/GOG-3041/ENGOT-EN10: a randomized phase III trial of first-line carboplatin (carb) and paclitaxel (pac) in combination with durvalumab (durva), followed by maintenance durva with or without olaparib (ola), in patients (pts) with newly diagnosed (nd) advanced or recurrent endometrial cancer (EC).

Journal of Clinical Oncology2020-05-208 citations